A 36 Month Multi-center, Open Label, Randomized, Comparator Study to Evaluate the Efficacy and Safety of Everolimus Immunosuppression Treatment in Liver Transplantation for Hepatocellular Carcinoma Exceeding Milan Criteria
Phase of Trial: Phase IV
Latest Information Update: 20 Feb 2017
At a glance
- Drugs Everolimus (Primary) ; Mycophenolate mofetil; Mycophenolic acid; Tacrolimus
- Indications Liver cancer
- Focus Therapeutic Use
- 11 Feb 2016 Planned End Date changed from 1 Jun 2018 to 1 Oct 2018 as per ClinicalTrials.gov record.
- 11 Feb 2016 Planned primary completion date changed from 1 Jun 2018 to 1 Oct 2018 as per ClinicalTrials.gov record.
- 07 May 2014 New trial record